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Abstract
Aims The long-term impact of coffee or tea consumption on subclinical left ventricular (LV) systolic or diastolic function has
not been previously studied. We examined the association between coffee or tea consumption beginning in early adulthood
and cardiac function in midlife.
Methods and results We investigated 2735 Coronary Artery Risk Development in Young Adults (CARDIA) study participants
with long-term total caffeine intake, coffee, and tea consumption data from three visits over a 20 year interval and available
echocardiography indices at the CARDIA Year-25 exam (2010–2011). Linear regression models were used to assess the asso-
ciation between caffeine intake, tea, and coffee consumption (independent variables) and echocardiography outcomes [LV
mass, left atrial volume, and global longitudinal strain (GLS), LV ejection fraction (LVEF), and transmitral Doppler early filling
velocity to tissue Doppler early diastolic mitral annular velocity (E/e´)]. Models were adjusted for standard cardiovascular risk
factors, socioeconomic status, physical activity, alcohol use, and dietary factors (calorie intake, whole and refined grain intake,
and fruit and vegetable consumption). Mean (standard deviation) age was 25.2 (3.5) years at the CARDIA Year-0 exam (1985–
1986), 57.4% were women, and 41.9% were African-American. In adjusted multivariable linear regression models assessing the
relationship between coffee consumption and GLS, beta coefficients when comparing coffee drinkers of <1, 1–2, 3–4, and >4
cups/day with non-coffee drinkers were β = 0.30%, P < 0.05; β = 0.35%, P < 0.05; β = 0.32%, P < 0.05; β = 0.40%,
P > 0.05; respectively (more negative values implies better systolic function). In adjusted multivariable linear regression
models assessing the relationship between coffee consumption and E/e´, beta coefficients when comparing coffee drinkers
of <1, 1–2, 3–4, and >4 cups/day with non-coffee drinkers were β = 0.29, P < 0.05; β = 0.38, P < 0.01; β = 0.20,
P > .05; and β = 0.37, P > 0.05, respectively (more negative values implies better diastolic function). High daily coffee con-
sumption (>4 cups/day) was associated with worse LVEF (β =1.69, P< 0.05). There were no associations between either tea
drinking or total caffeine intake and cardiac function (P > 0.05 for all).
Conclusions Low-to-moderate daily coffee consumption from early adulthood to middle age was associated with better LV
systolic and diastolic function in midlife. High daily coffee consumption (>4cups/day) was associated with worse LV function.
There was no association between caffeine or tea intake and cardiac function.
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Introduction
Coffee and tea are among the most widely consumed bever-
ages. More than half of adults in the United States drink at
least one cup of coffee each day, and this proportion is ex-
pected to increase with the aging of the population.1 Given
that a substantial amount of people drink coffee or tea, even
small cardiovascular benefits or risks associated with their
consumption may have significant population attributable
risk. An important area of scientific inquiry is the role of cof-
fee or tea consumption on heart failure (HF)—a leading
causes of morbidity and mortality that is projected to worsen
over the next decade.2 Studies examining the association be-
tween coffee or tea consumption and HF have been inconsis-
tent. Separate studies have shown positive, neutral, or
negative associations between these beverages and adverse
outcomes.3–7 Examining associations between coffee, caf-
feine, or tea consumption and subclinical cardiac dysfunction
may elucidate underlying mechanisms and provide further in-
sights about HF risk. In this context, it is well established that
antecedent cardiac dysfunction precedes the onset of overt
HF.8 We investigated the association between daily coffee,
caffeine, or tea consumption in the early adult lifespan and
subclinical cardiac function in middle age using data from
the Coronary Artery Risk Development in Young Adults (CAR-
DIA) study.
Methods
The CARDIA study is a community-based cohort study de-
signed to investigate the development and determinants of
cardiovascular disease in 5115 men and women initially aged
18–30 years at study baseline.9 Participants were recruited
between 1985 and 1986 (Year-0 exam) from four US commu-
nities (Birmingham, AL; Chicago, IL; Minneapolis, MN; and
Oakland, CA) and followed up in seven subsequent visits up
until 2011 in this analytical sample.9 All participants provided
written informed consent at each examination, and the insti-
tutional review boards of each institution approved the study
in compliance with the Declaration of Helsinki.
Study design and participant selection
Out of the 3498 participants who attended the CARDIA
Year-25 exam, participants with valvular dysfunction
(n = 32), implausibly high or low energy intake (n = 170)
(<800 or >8000 kcal/day for men, <600 or >6000 kcal/day
for women), missing dietary data or covariates (n = 561) were
excluded from analysis, resulting in an analytic study sample
of 2735 participants. Participants who were excluded were
more likely to be black, men, and smokers, but there was
no significant difference in baseline coffee or tea
consumption.
Coffee, caffeine, and tea consumption
assessment
The CARDIA study utilized validated interviewer-administered
dietary instruments, which have been described in prior
studies.10,11 Dietary history was obtained at Year-0, Year-7,
and Year-20. Participants were asked to report detailed food
intake patterns. Daily coffee, tea, and caffeine consumption
at CARDIA Year-0, Year-7, and Year-20 were utilized because
multiple points have been shown to be more precise esti-
mates of intake compared with a single assessment.10,11 Sim-
ilar to prior CARDIA analysis,11 daily total caffeine intake
(milligrammes per day) was calculated from all caffeine con-
taining beverages and foods reported and categorized in
quintiles. A cup of coffee or tea was considered to be approx-
imately 237mL or 8 oz. Daily coffee consumption was catego-
rized as <1, 1–2, 3–4, and >4 cups/day whereas tea
consumption was categorized as <1, 1–2, and >2
cups/day.11 The response rate for decaffeinated coffee was
low (<25%). The CARDIA dietary history assessments also
provided data on alcohol consumption, calorie intake, whole
and refined grain intake, and fruit and vegetable consump-
tion (servings/day).
Risk factor assessment
The CARDIA study risk factor assessments have been de-
scribed in previous studies.11 Briefly, three-seated blood pres-
sure measurements were obtained using a random zero
sphygmomanometer. The average of the second and third
measurements were used. Diabetes mellitus was ascertained
on the basis of one or more of a combination of a history of
medication use, fasting glucose ≥126 mg/dL, 2 h from a glu-
cose tolerance test (glucose ≥200 mg/dL), or glycated
haemoglobin ≥6.5. Smoking history was obtained from vali-
dated questionnaires. A physical activity score (exercise units)
was obtained from the CARDIA physical activity history, a
modified version of the Minnesota Leisure Time Physical Ac-
tivity Questionnaire. A score of 100 exercise units is equiva-
lent to 2 to 3 h/week of vigorous activity for 6 months of
the year. High-density lipoprotein cholesterol was quantified
using enzymatic assays, and low-density lipoprotein choles-
terol was derived from the Friedewald equation.
Echocardiography protocol
Experienced sonographers using a standardized protocol
across all field sites, performed an echocardiographic
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evaluation using an Artida cardiac ultrasound machine
(Toshiba Medical Systems, Otawara, Japan).12 Quality control
and image analysis were performed at an
echocardiography-reading centre (Johns Hopkins University,
Baltimore, Maryland). Traditional and tissue Doppler mea-
surements were made from digitized images using a stan-
dard offline image analysis software system (Digisonics,
Inc., Houston, Texas). Left ventricular (LV) mass (LVM), left
atrial volume (LAV), and LV ejection fraction (LVEF) were ob-
tained using recommendations from the American Society of
Echocardiography.13 LAV and LVM were indexed to body
surface area were derived from tissue Doppler e´ was ob-
tained from the average of septal and lateral annular veloc-
ities. Global longitudinal strain (GLS) was analysed on a
16-segment basis for the LV mid-wall layer performed offline
using two-dimensional wall motion tracking software
(UltraExtend, version 2.7; Toshiba Medical Systems,
Otawara, Japan). The average frame rate was 46.2 frames
per second with a mean heart rate <70 beats/min.14 A La-
grangian strain was derived from the change in regional
length relative to the length at end-diastole.14,15 Global
strain values were calculated as the average of segmental
peak strains. More GLS values imply better systolic function.
More negative e´ signifies impaired LV relaxation while a
more positive transmitral Doppler early filling velocity to tis-
sue Doppler early diastolic mitral annular velocity (E/e´) de-
notes worse diastolic function. The CARDIA
echocardiographic examination showed good reproducibility
profile.15
Statistical analysis
Characteristics of the study participants at Year-0, Year-7,
and Year-20 were summarized using mean and standard de-
viations, and categorical variables were expressed as fre-
quencies and percentages, as appropriate. The goals of the
analysis were to assess the association between consump-
tion of coffee, tea, total caffeine intake, and cardiac echo-
cardiography measures. Accordingly, multivariable linear
regression models using echocardiography measures as the
dependent variable were used to assess associations with
categories of coffee and tea intake. Covariates were derived
from mean values from multiple assessments across cohort
visits. Models were adjusted for age, sex, race, education,
and employment status, smoking history, body mass index,
systolic blood pressure, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol, diabetes, physical













Age, years (Year-0) 24.6 ± 3.7 24.8 ± 3.6 25.8 ± 3.3 26.2 ± 3.3 26.6 ± 2.9
Women, % 354 (58.2) 592 (61) 300 (56.4) 249 (54.9) 76 (44.4)
Caucasian % 269 (42.2) 434 (44.7) 364 (68.4) 369 (81.3) 154 (90.1)
Current smokers, % 71 (11.8) 118 (12.4) 71 (13.5) 75 (16.7) 47 (27.8)
Body mass index (kg/m2) 31.3 ± 7.8 30.3 ± 7.3 28.9 ± 6.5 29.5 ± 6.6 29.0 ± 5.9
Systolic blood pressure,
(mmHg)
120.1 ± 16.0 120.3 ± 16.7 117.3 ± 15.0 117.5 ± 15.2 119.1 ± 15.9
HDL Cholesterol, (mg/dL) 56.0 ± 17.2 57.5 ± 16.9 59.9 ± 17.7 60.4 ± 18.8 59.5 ± 21.5
LDL Cholesterol, (mg/dL) 110 ± 31.5 112.5 ± 33.5 114.1 ± 31.2 113.7 ± 31.6 110.4 ± 34.2
Non-tea drinkers 168(27.6) 138(14.2) 86(16.2) 72(15.9) 35(20.5)
<1 tea cups/day 332(54.6) 650(67.0) 369(69.4) 282(62.1) 103(60.2)
1–2 tea cups/day 62(10.2 114(11.8) 51(9.6) 68(15.0) 17(9.9)
>2 tea cups/day 46(7.6) 68(7.0) 26(4.9) 32(7.1) 16(9.4)
Total caffeine intake/day
(mg)
57.3 ± 68.4 91.6 ± 70.7 223.6 ± 76.9 418.2 ± 139.0 936.6 ± 531.1
Echocardiography indices
LV Mass (g) 174.1 ± 61.4 167.8 ± 52.2 166.1 ± 50.6 163.3 ± 44.2 171.0 ± 47.8
LA volume (mL) 50.6 ± 16.4 50.1 ± 16.1 48.6 ± 15.3 48.5 ± 13.8 49.6 ± 16.0
GLS (%) 14.7 ± 2.5 15.1 ± 2.5 15.4 ± 2.3 15.4 ± 2.3 15.4 ± 2.4
LVEF (%) 61.5 ± 7.1 61.9 ± 7.0 61.8 ± 6.7 62.0 ± 6.7 59.9 ± 7.2
E/e´ 8.11 ± 2.4 7.8 ± 2.3 7.5 ± 2.2 7.7 ± 2.0 7.5 ± 2.1
E/e´, ratio of transmitral inflow velocity to early diastolic mitral annular velocity; g, gramme; HDL, high-density lipoprotein; kg,
kilogramme; LA, left atrial; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; m2, metres squared; mg, milligramme;
mL, millilitres; GLS, global longitudinal strain.
Data are expressed as mean ± standard deviation or frequencies (proportion), as appropriate.
Coffee and tea consumption categories represent the mean values from three cohort visits (Year-0, Year-7, and Year-20). Population char-
acteristics are reported for the CARDIA examination Year-25 exam except tea and coffee, which represent the mean from three cohort
visits.
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activity, alcohol intake, and dietary factors (calorie intake,
whole grain intake, refined grain intake, and fruit and vege-
table consumption). In a secondary analysis, the relation be-
tween daily total caffeine intake (milligrammes) in quintiles
and cardiac structure and function were also assessed and
analysed similarly to the aforementioned regression models.
There were no observed race or sex differences. Variance in-
flation factor was utilized to assess for potential collinearity
of covariates in fully adjusted models. Analyses were per-
formed using SAS software version 9.4 (SAS Institute, Inc.,
NC) and STATA (StataCorp, version 15; StataCorp, College




Table 1 displays the population and echocardiographic char-
acteristics of 2735 study participants stratified by coffee
Figure 1 Histograms illustrating the distributions of coffee and tea consumption.
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consumption subgroups. Table S1 (Supporting Information)
shows the distribution of clinical characteristics across cohort
visits (Year-0, Year-7, and Year-20). Mean age at an analytical
baseline was 25.2 ± 3.5 years; 57.4% were women, and 58.4%
were Caucasian. Participants who consumed >4 cups/day of
coffee were more likely to be Caucasian and men. A higher
proportion of participants with >4 cups/day of coffee were
also current smokers (27.8%). Figure 1 shows a histogram il-
lustrating the distribution of coffee and tea consumption in
the study sample.
Coffee, tea, caffeine consumption, and cardiac
function
The association between coffee consumption and cardiac
structure and function is shown in Table 2. In adjusted multi-
variable linear regression models assessing the relationship
between coffee consumption and GLS, beta coefficients
when comparing coffee drinkers of <1, 1–2, 3–4, and >4
cups/day with non-coffee drinkers were β = 0.30%,
P < 0.05; β = 0.35%, P < 0.05; β = 0.32%, P < 0.05;
and β = 0.40%, P > 0.05; respectively (more negative values
implies better systolic function). In adjusted multivariable lin-
ear regression models assessing the relationship between
coffee consumption and E/e´, beta coefficients when compar-
ing coffee drinkers of <1, 1–2, 3–4, and >4 cups/day with
non-coffee drinkers were β = 0.29, P < 0.05; β = 0.38,
P < 0.01; β = 0.20, P > .05; β = 0.37, P > 0.05, respec-
tively (more negative values implies better diastolic function).
High daily coffee consumption (>4 cups/day) was associated
with worse LVEF β = 1.69, P < 0.05). There were no signif-
icant associations between coffee consumption and LVM or
LAV. As shown in Table 3, although tea consumption was re-
lated to lower LVM in unadjusted models, in fully adjusted
models accounting for confounding by cardiovascular risk fac-
tors, particularly socioeconomic status, there was no relation
between tea consumption and LVM. Tea consumption was
not significantly associated with any indices of cardiac struc-
ture and function. As shown in Table S2 (Supporting Informa-
tion), no evidence of an association was observed between
total caffeine intake and measures of cardiac structure and
function.
Discussion
In this large community-based cohort study of young adults
transitioning into middle age, our main findings were that
low-to-moderate daily coffee consumption was associated
with better subclinical systolic and diastolic function. (lower
LV E/e´ and better LV GLS). Conversely, we observed that a
high daily coffee consumption (>4 cups/day) was associated
with worse LV systolic function (lower LVEF). There were no
Figure 2 Coffee consumption from early adulthood to middle age and cardiac function in midlife. Description: Least squared means plots with 95%
confidence intervals for the showing of the association between coffee consumption in cups/day and global longitudinal strain (GLS) and E/e´. Plots
were derived from multivariable regression models. More negative or lower values of GLS and E/e´ signify better function. Low-to-moderate coffee
consumption was associated with better GLS and E/e´.
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associations between daily tea drinking or total caffeine in-
take and cardiac structure and function. Our study findings
remained statistically significant even after robust accounting
for confounding by standard cardiovascular risk factors; so-
cioeconomic status; physical activity; alcohol use; and dietary
factors (calorie intake, whole and refined grain intake, and
fruit and vegetable consumption). This is the first study to
demonstrate that long-term low-to-moderate coffee con-
sumption was associated with better subclinical cardiac func-
tion—an observation that may represent an underlying
pathophysiological pathway for noted associations between
moderate coffee consumption and HF.
Coffee consumption typically in early adulthood. In fact, by
ages 18 to 24 years, one out of two individuals in the USA al-
ready consume coffee on a daily basis.1 It is noteworthy that
the CARDIA study recruited participants from age 18 to
30 years, limiting prevalent exposure bias that may occur be-
fore the onset of the study.9
Our results are particularly relevant because early adult-
hood represents a crucial window to mitigate the influence
of aging-related cardiac risk factors on cardiovascular health
through dietary modifications, lifestyle changes, or medical
therapy.
Several lines of evidence from observational studies, but
not all, support an inverse association between habitual
coffee and tea consumption and clinical outcomes.5,16–18
Studies comprising of data from predominantly European
cohorts have investigated the association between coffee
consumption and HF. These studies noted a U-shaped asso-
ciation with reduced risk of HF in persons who drink 4 cof-
fee cups/day, but an increased HF risk with consumption of
>10 cups/day.3 Results from these European studies are
Table 2 Association between coffee consumption and cardiac structure and function
Beta estimate (standard error)
LVMi LVMi
Coffee consumption Univariate (R2 0.0016) Multivariable (R2 0.20)
Non-coffee drinkers Reference Reference
<1 cup/day 1.19(1.2) 0.08(1.1)
1–2 cups/day 1.19(1.3) 0.11(1.3)
3–4 cups/day 2.53(1.4) 1.23(1.3)
>4 cups/day 0.39 (2.0) 0.57(1.9)
LAVi LAVi
Coffee consumption Univariate (R2 0.0015) Multivariable (R2 0.05)
Non-coffee drinkers Reference Reference
<1 cup/day 0.25 (0.4) 0.32(0.4)
1–2 cups/day 0.31 (0.4) 0.17(0.4)
3–4 cups/day 0.44(0.4) 0.18(0.5)
>4 cups/day 0.31(0.6) 0.008(0.6)
GLS GLS
Coffee consumption Univariate (R2 0.012) Multivariable (R2 0.12)
Non-coffee drinkers Reference Reference
<1 cup/day 0.38(0.1)** 0.30(0.1)*
1–2 cups/day 0.65 (0.2)*** 0.35(0.1)*
3–4 cups/day 0.72 (0.2)*** 0.32(0.1)*
>4 cups/day 0.71 (0.22)** 0.40(0.2)
LVEF LVEF
Coffee consumption Univariate (R2 0.005) Multivariable (R2 0.029)
Non-coffee drinkers Reference Reference
<1 cup/day 0.42(0.4) 0.36(0.4)
1–2 cups/day 0.33(0.4) 0.10(0.4)
3–4 cups/day 0.54(0.4) 0.28(0.5)
>4 cups/day 1.52(0.6)* 1.69(0.6)*
E/e´ E/e´
Coffee consumption Univariate (R2 0.01) Multivariable (R2 0.15)
Non-coffee drinkers Reference Reference
<1 cup/day 0.34(0.1)** 0.29(0.1)*
1–2 cups/day 0.64(0.1)*** 0.38(0.1)**
3–4 cups/day 0.43(0.1)** 0.20(0.1)
>4 cups/day 0.58(0.2)** 0.37(0.2)
LV, left ventricular; LVMi, LV mass indexed to body surface area; LAVi, left atrial volume indexed to body surface area; GLS, global longi-
tudinal strain; EF, ejection fraction; E/e´, ratio of peak early diastolic velocity (E) and early peak diastolic mitral annular velocity (e’)
Multivariable linear regression models showing association between coffee consumption and cardiac structure and function. Models were
adjusted for age, sex, race, education, employment status, smoking, body mass index, systolic blood pressure, high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), diabetes, physical activity, alcohol intake, calorie intake, whole grain in-
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similar to ours and should be interpreted in the context
that the size of a standard cup of coffee in the USA is typ-
ically about two times larger than the standard serving size
in Europe.19 Our study findings of neutral or detrimental
associations with LV function among high daily coffee
drinkers reinforce the importance of moderation in coffee
drinking. In the current study, there was no relationship
between coffee consumption and LVM. The reason for this
lack of association is not clear, but it may be reasonable to
theorize that coffee consumption may be closer related to
LV functional rather than structural alterations in early
adulthood. Because of a low response rate, we were un-
able to reliably assess the independent role of decaffein-
ated coffee. However, we observed that daily total
caffeine intake (obtained from all dietary sources) was not
associated with LV function. Consistent with this finding,
in a prior report of 9.2 million adults, it was observed that
accounting for variations in genetic polymorphisms that
also influence caffeine metabolism, did not modify
mortality risk with coffee consumption.20 Taken together
with our findings is highlighted. Although we noted a
favourable association between tea drinking and LVM in
unadjusted models, this association was not statistically
significant in models that accounted for confounding
factors, particularly socioeconomic status. A majority of
studies accessing the benefits of tea drinking have focused
on green tea consumption. We speculate that this may be
partly related to the observation that black tea (which is
more prevalent in western populations such as ours), con-
tains less chemo-protective agents when compared with
green tea.21
Potential mechanisms
Several explanatory mechanisms that may explain an associ-
ation between coffee consumption and subclinical cardiac
function exist. From a biological perspective, beyond
Table 3 Association between tea consumption and cardiac structure and function
Beta estimate (standard error)
LVMi LVMi
Tea consumption Univariate (R2 0.008) Multivariable (R2 0.20)
Non-tea drinkers Reference Reference
<1 cup/day 4.9(1.1)*** 1.95(1.1)
1–2 cups/day 5.1(1.6)** 1.12(1.5)
>2cups/day 5.4 (1.9)** 0.69(1.8)
LAVi LAVi
Tea consumption Univariate (R2 0.003) Multivariable (R2 0.05)
Non-tea drinkers Reference Reference
<1 cup/day 0.06(0.4) 0.07 (0.37)
1–2 cups/day 0.60(0.5) 0.48(0.5)
>2cups/day 1.21(0.6)* 1.09(0.6)
GLS GLS
Tea consumption Univariate (R2 0.0018) Multivariable (R2 0.12)
Non-tea drinkers Reference Reference
<1 cup/day 0.16(0.1) 0.05(0.1)
1–2 cups/day 0.35(0.2) 0.004(0.2)
>2cups/day 0.33(0.2) 0.05(0.2)
LVEF LVEF
Tea consumption Univariate (R2 0.0006) Multivariable (R2 0.024)
Non-tea drinkers Reference Reference
<1 cup/day 0.16(0.4) 0.05(0.4)
1–2 cups/day 0.15(0.5) 0.4 (0.5)
>2cups/day 0.64(0.6) 0.23(0.6)
E/e´ E/e´
Tea consumption Univariate (R2 0.001) Multivariable (R2 0.15)
Non-tea drinkers Reference Reference
<1 cup/day 0.09(0.1) 0.08(0.1)
1–2 cups/day 0.25(0.2) 0.07(0.2)
>2cups/day 0.04(0.2) 0.31(0.19)
LV, left ventricular; LVMi, LV mass indexed to body surface area; LAVi, left atrial volume indexed to body surface area; GLS, global longi-
tudinal strain; LVEF, LV ejection fraction; E/e´, ratio of peak early diastolic velocity (E) and early peak diastolic mitral annular velocity (e´).
Multivariable linear regression models showing the association between tea consumption and cardiac structure and function. Models
were adjusted for age, sex, race, education, employment status, smoking, body mass index, systolic blood pressure, high-density lipopro-
tein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), diabetes, physical activity, alcohol intake, calorie intake, whole grain
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caffeine, coffee contains bioactive substances such as flavo-
noids, diterpenes, and melanoidins that can modulate anti-
oxidant effects, increase nitric oxide production, and
superoxide free-radicals scavenging.22,23 Experimental stud-
ies suggest that flavonoids—present in coffee—modulate
gene expression and signalling pathways such as enhance-
ment and activation of 5-monophosphate-activated protein
kinase, increased toll-like receptor-4 expression, increased
nitrite oxidase synthase, and reduced production of reactive
oxygen species.23 Further potentiation of these
chemo-protective properties can occur when the gut inter-
acts with a colonic microbiome and metabolic conversion
to smaller more potent phenolic substances than their par-
ent compounds occur.24 The molecular attributes of these
cellular proteins and signalling pathways influence other
downstream pleiotropic effects such as decreased arterial
stiffness,25 reductions in LDL cholesterol,26 lower insulin re-
sistance, improved glycemic control, and a lower risk of
metabolic syndrome and diabetes mellitus.19 Although tran-
sient increases in blood pressure following short-term ad-
ministration of coffee has been noted,27 it has not
translated to a long-term risk for hypertension.28 It is spec-
ulated that with long-term coffee consumption, there is a
counterbalancing effect of non-caffeine constituents that
augments an increased tolerance to acute hemodynamic ef-
fects of coffee.29
Study strengths and limitations
The clear strengths of this study included recruitment of
participants in early adulthood; inclusion of a biracial cohort
of community-dwelling individuals; estimation of coffee
consumption at multiple time points; comprehensive ac-
counting for confounders such as cardiovascular disease risk
factors; socioeconomic status; physical activity; dietary and
calorie intake; and echocardiographic assessment in a large
community-based sample. Our study observations do not
aim to infer causality. Furthermore, coffee or tea subtypes,
brewing methods, and epigenetic effects were not
assessed. The role of decaffeinated coffee could not be in-
dependently assessed in the present study because a low
response rate, but we were able to examine total caffeine
consumptions from all sources and contrast it with the con-
sumption of any coffee subtype. Our cross-sectional analy-
sis did not adjust for echocardiography indicators at study
enrolment. We were also unable to assess differences by
the degree of fermentation during tea processing, which
may play a contributory role. Long-term observational co-
hort studies such as ours can be susceptible to nonre-
sponse over time; however, the CARDIA study showed
good cohort retention and followed rigorous quality control
protocols.15
Conclusions
Our observations in this community-based sample under-
score an association between low-to-moderate coffee con-
sumption from early adulthood to middle age and
favourable changes in LV systolic and diastolic function in
midlife. High coffee consumption (>4 cups/day) was how-
ever associated with worse LV systolic function. There was
no relation between tea or caffeine intake and cardiac
function.
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CLINICAL PERSPECTIVE
Competency in Medical Knowledge
Low-to-moderate consumption of coffee from early adult-
hood to midlife was associated with better left ventricular
systolic and diastolic function in middle age, which may partly
underlie observations of a reduced risk of clinical HF. How-
ever, long-term excessive coffee consumption is associated
with deleterious effects on cardiac function. The present
study findings highlight the importance of moderation in cof-
fee drinking in order to reap the cardiovascular benefits and
potentially avoid harm.
Translational Outlook
Additional research is needed to clarify the epigenetic and
contributory factors that may modulate the
dose-dependent effects of coffee consumption on the human
heart.
8 C.C. Nwabuo et al.
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12684
Supporting information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Population characteristics of study participants
(N = 2735).
Table S2. Association between total caffeine intake and car-
diac structure and function.
Table S3. Characteristics of included and not included coro-
nary artery risk development in young adults study partici-
pants at study enrollment (n = 5115).
References
1. Loftfield E, Freedman ND, Dodd KW,
Vogtmann E, Xiao Q, Sinha R, Graubard
BI. Coffee drinking is widespread in the
United States, but usual intake varies
by key demographic and lifestyle factors.
J Nutr 2016; 146: 1762–1768.
2. Benjamin EJ, Muntner P, Alonso A,
Bittencourt MS, Callaway CW, Carson
AP, Chamberlain AM, Chang AR, Cheng
S, Das SR, Delling FN, Djousse L, Elkind
MSV, Ferguson JF, Fornage M, Jordan
LC, Khan SS, Kissela BM, Knutson KL,
Kwan TW, Lackland DT, Lewis TT,
Lichtman JH, Longenecker CT, Loop
MS, Lutsey PL, Martin SS, Matsushita
K, Moran AE, Mussolino ME, O’Flaherty
M, Pandey A, Perak AM, Rosamond
WD, Roth GA, Sampson UKA, Satou
GM, Schroeder EB, Shah SH, Spartano
NL, Stokes A, Tirschwell DL, Tsao CW,
Turakhia MP, VanWagner LB, Wilkins
JT, Wong SS, Virani SS. Heart disease
and stroke statistics—2019 update: a re-
port from the American Heart Associa-
tion. Circulation 2019 Mar 5; 139:
e56–e528.
3. Mostofsky E, Rice MS, Levitan EB,
Mittleman MA. Habitual coffee con-
sumption and risk of heart failure: a
dose-response meta-analysis. Circ Heart
Fail 2012; 5: 401–405.
4. Wilhelmsen L, Rosengren A, Eriksson H,
Lappas G. Heart failure in the general
population of men--morbidity, risk fac-
tors and prognosis. J Intern Med 2001;
249: 253–261.
5. Ahmed HN, Levitan EB, Wolk A,
Mittleman MA. Coffee consumption
and risk of heart failure in men: an anal-
ysis from the cohort of Swedish Men. Am
Heart J 2009; 158: 667–672.
6. Peters U, Poole C, Arab L. Does tea affect
cardiovascular disease? A meta-analysis.
Am J Epidemiol 2001; 154: 495–503.
7. Zhang C, Qin YY, Wei X, Yu FF, Zhou YH,
He J. Tea consumption and risk of car-
diovascular outcomes and total mortal-
ity: a systematic review and
meta-analysis of prospective observa-
tional studies. Eur J Epidemiol 2015;
30: 103–113.
8. Nwabuo CC, Armstrong AAC, Ambale-
Venkatesh B, Vasconcellos HD, Mewton
N, Lima JAC, Moreira HT, Opdahl A,
Lloyd-Jones D, Ogunyankin KO, Jacobs
DR Jr, Schreiner PJ, Lewis CE, Gidding
SS. Left ventricular global function in-
dex predicts incident heart failure and
cardiovascular disease in young adults:
the Coronary Artery Risk Development
in Young Adults (CARDIA) study. Eur
Heart J Cardiovasc Imaging 2018; 20:
533–540.
9. Friedman GD, Cutter GR, Donahue RP,
Hughes GH, Hulley SB, Jacobs DR Jr,
Liu K, Savage PJ. CARDIA: study design,
recruitment, and some characteristics of
the examined subjects. J Clin Epidemiol
1988; 41: 1105–1116.
10. Liu K, Slattery M, Jacobs D Jr, Cutter G,
McDonald A, Van Horn L, Hilner JE,
Caan B, Bragg C, Dyer A. A study of the
reliability and comparative validity of
the cardia dietary history. Ethn Dis
1994 Winter; 4: 15–27.
11. Reis JP, Loria CM, Steffen LM, Zhou X,
van Horn L, Siscovick DS, Jacobs DR Jr,
Carr JJ. Coffee, decaffeinated coffee,
caffeine, and tea consumption in young
adulthood and atherosclerosis later in
life: the CARDIA study. Arterioscler
Thromb Vasc Biol 2010; 30: 2059–2066.
12. Nwabuo CC, Moreira HT, Vasconcellos
HD, Ambale-Venkatesh B, Yoneyama K,
Ohyama Y, Sharma RK, Armstrong AC,
Ostovaneh MR, Lewis CE, Liu K,
Schreiner PJ, Ogunyankin KO, Gidding
SS, Lima JAC. Association of aortic root
dilation from early adulthood to middle
age with cardiac structure and function:
the CARDIA study. J Am Soc
Echocardiogr 2017; 30: 1172–1179.
13. Lang RM, Badano LP, Mor-Avi V, Afilalo
J, Armstrong A, Ernande L, Flachskampf
FA, Foster E, Goldstein SA, Kuznetsova
T, Lancellotti P, Muraru D, Picard MH,
Rietzschel ER, Rudski L, Spencer KT,
Tsang W, Voigt JU. Recommendations
for cardiac chamber quantification by
echocardiography in adults: an update
from the American Society of Echocardi-
ography and the European Association
of Cardiovascular Imaging. J Am Soc
Echocardiogr 2015 Jan; 28: 1–39.e14.
14. Moreira HT, Nwabuo CC, Armstrong AC,
Kishi S, Gjesdal O, Reis JP, Schreiner PJ,
Liu K, Lewis CE, Sidney S, Gidding SS,
Lima JAC, Ambale-Venkatesh B. Refer-
ence ranges and regional patterns of left
ventricular strain and strain rate using
two-dimensional speckle-tracking echo-
cardiography in a healthy middle-aged
black and white population: the CARDIA
study. J Am Soc Echocardiogr 2017 Jul;
30: 647–658.e642.
15. Armstrong AC, Ricketts EP, Cox C, Adler
P, Arynchyn A, Liu K, Stengel E, Sidney
S, Lewis CE, Schreiner PJ, Shikany JM,
Keck K, Merlo J, Gidding SS, Lima JA.
Quality control and reproducibility in
M-mode, two-dimensional, and speckle
tracking echocardiography acquisition
and analysis: the CARDIA study, Year
25 examination experience. Echocardi-
ography 2015; 32: 1233–1240.
16. Wang Y, Tuomilehto J, Jousilahti P,
Antikainen R, Mahonen M, Mannisto S,
Katzmarzyk PT, Hu G. Coffee consump-
tion and the risk of heart failure in Finn-
ish men and women. Heart 2011; 97:
44–48.
17. Levitan EB, Ahmed HN, Mittleman MA,
Wolk A. Coffee consumption and inci-
dence of heart failure in women. Circ
Heart Fail 2011; 4: 414–418.
18. Ding M, Bhupathiraju SN, Satija A, van
Dam RM, Hu FB. Long-term coffee con-
sumption and risk of cardiovascular dis-
ease: a systematic review and a
dose-response meta-analysis of prospec-
tive cohort studies. Circulation 2014;
129: 643–659.
19. van Dam RM, Hu FB. Coffee consump-
tion and risk of type 2 diabetes: a sys-
tematic review. JAMA 2005; 294:
97–104.
20. Loftfield E, Cornelis MC, Caporaso N, Yu
K, Sinha R, Freedman N. Association of
coffee drinking with mortality by ge-
netic variation in caffeine metabolism:
findings from the UK biobank. JAMA In-
tern Med 2018; 178: 1086–1097.
21. Ramadan G, El-Beih NM, Abd El-Ghffar
EA. Modulatory effects of black v. green
tea aqueous extract on hyperglycaemia,
hyperlipidaemia and liver dysfunction
in diabetic and obese rat models. Br J
Nutr 2009; 102: 1611–1619.
22. Yanagimoto K, Ochi H, Lee KG,
Shibamoto T. Antioxidative activities
of fractions obtained from brewed cof-
fee. J Agric Food Chem 2004; 52:
592–596.
23. Mozaffarian D, Wu JHY. Flavonoids,
dairy foods, and cardiovascular and
Coffee and tea consumption in the early adult lifespan and left ventricular function in middle age: the CARDIA study 9
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12684
metabolic health: a review of emerging
biologic pathways. Circ Res 2018; 122:
369–384.
24. Mosele JI, Macia A, Motilva MJ. Meta-
bolic and microbial modulation of the
large intestine ecosystem by
non-absorbed diet phenolic compounds:
a review. Molecules 2015; 20:
17429–17468.
25. Lin QF, Qiu CS, Wang SL, Huang LF,
Chen ZY, Chen Y, Chen G. A
cross-sectional study of the relationship
between habitual tea consumption and
arterial stiffness. J Am Coll Nutr 2016-
Jun; 35: 354–361.
26. Zhao Y, Asimi S, Wu K, Zheng J, Li D.
Black tea consumption and serum cho-
lesterol concentration: systematic re-
view and meta-analysis of randomized
controlled trials. Clin Nutr 2015; 34:
612–619.
27. Jee SH, He J, Whelton PK, Suh I, Klag
MJ. The effect of chronic coffee drinking
on blood pressure: a meta-analysis of
controlled clinical trials. Hypertension
1999; 33: 647–652.
28. Klag MJ, Wang NY, Meoni LA, Brancati
FL, Cooper LA, Liang KY, Young JH, Ford
DE. Coffee intake and risk of hyperten-
sion: the Johns Hopkins precursors
study. Arch Intern Med 2002; 162:
657–662.
29. Riksen NP, Rongen GA, Smits P. Acute
and long-term cardiovascular effects of
coffee: implications for coronary heart
disease. Pharmacol Ther 2009; 121:
185–191.
10 C.C. Nwabuo et al.
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12684
